十二月 2025
- Home
- Neclife
十二月 2025的Neclife市场份额分析
Nectar Lifesciences Limited is a pharmaceutical company in India that manufactures generic drug products. The company has global leadership in several oral and sterile cephalosporin drugs, and has cGMP facilities along with those approved by the European Union and Japan.
Neclife(包含公司地区分支机构)
查看更多网站流量和参与度信息- neclife.com
Neclife收入截至 十二月 2025为 2M - 5M
Neclife主要域名产生的收入
3 年中Neclife主要域名的收入
Neclife主要域名的收入
Neclife热门域名的总访问量
了解Neclife市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Neclife热门域名的平均访问时长
分析Neclife参与度指标。
过去 3 个月的平均访问时长
子公司明细
Neclife热门域名的平均页面浏览量
了解Neclife如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Neclife 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Nectar Lifesciences Ltd hired Ajit Singh Dhillon as additional director on Feb 13th '21.The Board of Nectar Lifescience at its meeting held on 13 February 2021 has appointed Dr. Ajit Singh Dhillon (DIN 09032214) on the Board as an additional director (independent) of the company till the date of forthcoming Annual General Meeting in which he can be appointed as a regular Independent Director.
二月 13, 2021阅读更多
新闻Nectar Lifesciences Ltd hired Dinesh Dua as CEO on Jan 1st '13.In 2013 Dinesh Dua was appointed CEO of Nectar Lifesciences Limited ( NSE:NECLIFE ).
二月 17, 2020阅读更多
查看 Neclife 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。